THE UNIVERSITY OF NOTTINGHAM
www.nottingham.ac.uk


The University of Nottingham, described by The Sunday Times University Guide 2011 as ‘the embodiment of the modern international university’, has 42,000 students at award-winning campuses in the United Kingdom, China and Malaysia. It is also the most popular university in the UK by 2012 application numbers, and ‘the world’s greenest university’.

It is ranked in the UK's Top 10 and the World's Top 75 universities by the Shanghai Jiao Tong (SJTU) and the QS World University Rankings. More than 90 per cent of research at The University of Nottingham is of international quality, according to the most recent Research Assessment Exercise.

The University aims to be recognised around the world for its signature contributions, especially in global food security, energy & sustainability, and health. The University won a Queen’s Anniversary Prize for Higher and Further Education in 2011, for its research into global food security.

Impact: The Nottingham Campaign, its biggest ever fund-raising campaign, will deliver the University’s vision to change lives, tackle global issues and shape the future. http://www.nottingham.ac.uk/news/index.aspx

Prof NIGEL MINTON

https://www.nottingham.ac.uk/cbs/people/nigel.minton


Nigel P Minton (Professor of Applied Molecular Microbiology) is a relative newcomer to academia. He established the Clostridia Research Group (CRG) in 2004, following 25 years of service in the applied environment of the Centre for Applied Microbiology and Research (CAMR), Porton Down. To date He has filed 15 patents, secured >£30M in funding since arriving at Nottingham, leads one of the six programmes that together comprise the BBSRC Sustainable Bioenergy Centre (BSBEC), is the PI of a recently awarded BBSRC sLoLa in Synthetic Biology and the director of a newly established £14.3M BBSRC/EPSRC Synthetic Biology Research Centre (SBRC) focussed on the sustainable production of platform chemicals from wastes and renewables. He is on the LanzaTech Scientific Advisory Board, consults for Pfizer, MERCK and Ipsen Pharmaceuticals and is the scientific lead on Clostridium difficile research within Nottingham’s NIHR Biomedical Research Unit on Gastrointestinal disease (£7.5M over 5 years).